Metastatic chondrosarcoma is a serious form of bone cancer that has spread beyond its original location to other parts of the body. Understanding this condition, its progression, and the available approaches to care can help patients and families navigate the challenges ahead with greater clarity and support.

What Is Metastatic Chondrosarcoma?

Chondrosarcoma is a type of bone cancer that begins in cartilage cells, which are the smooth tissues that cushion the ends of bones and line most joints. When this cancer spreads from its original site to distant parts of the body, it becomes metastatic chondrosarcoma. This spreading process is called metastasis, and it represents a more advanced stage of the disease.^[1]

The cancer cells can break away from the primary tumor and travel through the bloodstream or lymphatic system to reach other organs. When chondrosarcoma metastasizes, it most commonly spreads to the lungs and to other bones in the body. This pattern of spread significantly affects how the disease is managed and what outcomes patients can expect.^[5][16]

Chondrosarcoma itself is considered rare, affecting approximately 600 people each year in the United States. It accounts for about 20 percent of all primary malignant bone tumors, making it the second most common type of primary bone cancer in adults after multiple myeloma and osteosarcoma.^[2][19]

Epidemiology: Who Gets Metastatic Chondrosarcoma?

Chondrosarcoma is predominantly a disease of adulthood and older age. Most people receive their diagnosis when they are over 50 years old, with the average age at diagnosis being around 51 years. The condition is extremely rare in people younger than 20 years of age, and risk increases steadily with age until about 75 years.^[2][7]

The disease affects men and women nearly equally, with only a slight male predominance reported in some studies. There is no clear pattern showing that one gender is dramatically more affected than the other.^[1][2]

Certain rarer forms of chondrosarcoma, such as mesenchymal chondrosarcoma, tend to affect younger adults, often between the ages of 19 and 30. These subtypes behave differently from the more common forms and may have different patterns of spread.^[2]

The original tumor most commonly develops in bones of the axial skeleton, which includes the pelvis, shoulder blades, sternum (breastbone), and ribs. It can also appear in the long bones of the body, particularly the upper arm bone and thigh bone. Tumors in the hands and feet are quite rare.^[2][10]

Causes and Risk Factors

The exact cause of chondrosarcoma remains unknown to medical researchers. Scientists believe there may be genetic changes or mutations that make some people more susceptible to developing this cancer, but no single definitive cause has been identified.^[1][4]

Most cases of chondrosarcoma are sporadic, meaning they occur randomly without a clear inherited pattern. However, the cancer can sometimes develop from benign (noncancerous) bone or cartilage tumors that undergo malignant transformation over time.^[2]

Several benign bone and cartilage conditions are associated with increased risk of developing chondrosarcoma. Enchondroma is a benign bone tumor that starts in cartilage and often affects the hands and feet, though it can develop in other bones. The cause is unknown, but these tumors can occasionally become cancerous.^[1][7]

Ollier disease, also called enchondromatosis, is a rare condition that causes clusters of enchondromas, most commonly in the hands and feet. It is most common in children and young adults. This disease can cause severe bone deformities and fractures. About one in three people with Ollier disease will eventually develop chondrosarcoma.^[1][7]

Maffucci syndrome is an extremely rare condition that causes multiple enchondromas, usually affecting the hands and feet, along with benign tumors made up of blood vessels called angiomas. This syndrome significantly increases the risk of chondrosarcoma and other types of cancer.^[1][7]

Multiple hereditary exostoses is an inherited syndrome that causes many osteochondromas, which are overgrowths of cartilage and bone near the ends of long bones in the arms or legs. About 5 percent of these bone defects can transform into chondrosarcoma.^[1][2][7]

Certain genetic disorders also increase risk. People with Li-Fraumeni syndrome, a hereditary condition that predisposes individuals to various cancers, are more likely to develop chondrosarcoma among other cancerous tumors.^[1]

At the cellular level, researchers have detected chromosomal abnormalities in some types of chondrosarcomas. These include changes in chromosomes 9p21, 10, 13q14, and 17p13. Genetic instability and amplification of certain genes like MYC appear to play a role in how the disease develops, though much remains to be understood.^[2][10]

Symptoms of Metastatic Chondrosarcoma

Because most chondrosarcomas grow slowly, symptoms often develop gradually over months or even years. The progression of symptoms can be subtle at first, which sometimes leads to delays in diagnosis. When the cancer has metastasized, symptoms may come from both the original tumor site and the locations where the cancer has spread.^[4]

The most common symptom is bone pain that has a deep, dull, and aching quality. This pain typically comes and goes at first but gradually becomes more persistent. It often worsens at night, which can interfere with sleep. Unlike pain from an injury, this discomfort does not improve with rest and tends to get worse over time.^[5][7][16]

A noticeable lump or area of swelling may develop over the affected bone. This mass can sometimes be seen or felt through the skin, particularly when the tumor is located in an arm, leg, or rib. As the tumor grows, the swelling may become more pronounced.^[1][5][16]

Patients may experience a feeling of pressure around the lump or tumor site. Joint stiffness and limited range of motion can occur when tumors grow close to joints, disturbing normal joint function. Weakness in the affected limb may develop, and some people find it difficult to perform everyday activities.^[7]

When tumors are large or aggressive, nighttime pain becomes particularly common. This type of pain can be severe enough to wake someone from sleep and significantly affects quality of life.^[5][16]

For tumors located in the pelvis or spine, symptoms can include problems with bladder or bowel control if the tumor presses on the spinal cord or nearby nerves. Dysfunction of major nerves, such as the sciatic or femoral nerves, can occur with pelvic tumors near neurovascular bundles, causing pain, numbness, or weakness radiating down the legs.^[7][8]

General symptoms that may accompany metastatic disease include unintended weight loss and persistent fatigue. These systemic symptoms reflect the body’s response to widespread cancer.^[1]

When chondrosarcoma has metastasized to the lungs, respiratory symptoms may develop. A rapidly growing mass in the lungs, sometimes with unusual calcification patterns, can be detected on imaging. Patients may not always have obvious breathing symptoms initially, but as lung involvement progresses, shortness of breath or cough may appear.^[9]

Prevention and Early Detection

Because the exact cause of chondrosarcoma is unknown, there are no proven prevention strategies that can completely eliminate the risk of developing this cancer. However, people with known risk factors, particularly those with benign bone or cartilage conditions, benefit from careful monitoring.^[1]

Individuals diagnosed with conditions such as enchondroma, Ollier disease, Maffucci syndrome, or multiple hereditary exostoses should maintain regular follow-up appointments with their healthcare providers. Monitoring these benign tumors allows doctors to detect any changes that might suggest malignant transformation at an earlier, more treatable stage.^[1][7]

Anyone experiencing persistent bone pain that does not improve, especially pain that worsens at night or is accompanied by swelling, should seek medical evaluation promptly. While these symptoms do not always indicate cancer, early medical attention ensures that serious conditions are not overlooked. If a lump or mass does not go away within two weeks, or if unexplained fatigue persists, consulting a healthcare provider is important.^[1]

For people with inherited genetic syndromes associated with increased cancer risk, genetic counseling may provide valuable information about monitoring strategies and what symptoms to watch for. Understanding personal risk factors helps individuals and their healthcare teams develop appropriate surveillance plans.^[1]

Pathophysiology: How the Disease Develops and Spreads

Chondrosarcoma develops when cartilage cells undergo changes in their DNA that cause them to grow and multiply out of control. These abnormal cells accumulate to form a tumor. The instructions in a cell’s DNA normally regulate when cells should grow, divide, and die. When mutations disrupt these instructions, cells can begin to multiply rapidly and continue living when healthy cells would naturally die.^[4]

As the tumor grows, it can invade and destroy normal bone and tissue around it. The cancerous cells have the ability to break away from the primary tumor and enter the bloodstream or lymphatic system. Once in circulation, these cells can travel to distant parts of the body and establish new tumors, a process called metastasis.^[1]

The likelihood of metastasis is strongly linked to the grade of the tumor, which reflects how abnormal the cancer cells look under a microscope and how quickly they are likely to grow. Chondrosarcomas are classified into three grades. Grade 1 tumors are low-grade cancers that grow slowly and rarely spread. Grade 2 tumors are intermediate-grade and have a moderate risk of spreading. Grade 3 tumors are high-grade cancers that grow rapidly and have a significant risk of metastasis.^[8]

Grade 1 chondrosarcomas rarely metastasize. Grade 2 tumors carry approximately a 20 percent risk of spreading to other parts of the body. Grade 3 chondrosarcomas have a greater than 60 percent risk of metastasis, making them particularly aggressive and difficult to treat.^[5][16]

When chondrosarcoma metastasizes, the lungs are the most common destination. Cancer cells that enter the bloodstream often lodge in the small blood vessels of the lungs, where they can grow into new tumors. Other bones throughout the body are the second most common site of metastasis.^[5][16]

The location of the original tumor also influences outcomes. Tumors in the pelvis often grow to larger sizes before they are detected because symptoms may be vague or attributed to other causes. Pelvic tumors are also more difficult to remove surgically with clear margins, meaning that some cancer cells may be left behind. These factors contribute to higher rates of both local recurrence and distant metastasis for pelvic chondrosarcomas.^[5][16]

Different subtypes of chondrosarcoma behave in distinct ways. Conventional chondrosarcoma, which accounts for 85 to 90 percent of cases, generally grows slowly and has a lower tendency to spread compared to other subtypes. Dedifferentiated chondrosarcoma is a more aggressive variant where parts of the tumor transform into high-grade cells similar to other types of sarcoma. These tumors grow and spread rapidly. Mesenchymal chondrosarcoma is another aggressive subtype that often develops in the spine, ribs, or jaw and has a high likelihood of spreading. Clear cell chondrosarcoma tends to grow slowly and rarely metastasizes.^[2][10]

At the molecular level, genetic and chromosomal abnormalities drive the cancer’s behavior. Structural changes in chromosomes and genetic instability have been found in well-differentiated chondrosarcomas. The amplification of certain transcription factors plays a vital role in the cancer’s development and progression, though research is ongoing to fully understand these mechanisms.^[2][10]

Prognosis and Survival in Metastatic Chondrosarcoma

The outlook for patients with metastatic chondrosarcoma is considerably less favorable than for those with localized disease. Chondrosarcoma that has spread to distant sites at the time of diagnosis has a very poor prognosis overall.^[6][22]

Survival rates depend heavily on tumor grade and the presence of metastasis. For chondrosarcoma in general, about 79 percent of people are alive five years after diagnosis. However, this overall statistic includes many patients with localized, low-grade tumors. When cancer has metastasized, survival rates drop significantly.^[20]

High-grade tumors, particularly grade 3 chondrosarcomas, are more likely to spread and have poorer outcomes. More than 50 percent of grade 3 tumors metastasize. The one-year survival rate for dedifferentiated chondrosarcoma, one of the most aggressive subtypes, is only about 10 percent.^[8][12]

Research examining patients who had metastatic disease at the time of diagnosis has sought to identify factors that influence survival. Studies have found that certain characteristics, such as the tumor’s location, size, and response to treatment, play important roles in determining how long patients survive after diagnosis. However, the overall outlook remains challenging even with aggressive treatment.^[6][22]

Because of the rarity of chondrosarcoma and the complexity of treating metastatic disease, patients should seek evaluation and care from orthopaedic oncologists who specialize in bone cancers. These specialists often work in multidisciplinary teams that include surgical oncologists, radiation oncologists, and medical oncologists who can provide expertise in chemotherapy when appropriate.^[5][16]

Treatment Approaches for Metastatic Chondrosarcoma

Surgery remains the primary and most important treatment for chondrosarcoma. Complete surgical removal of the tumor with wide margins offers the best chance for controlling the disease. However, when cancer has already metastasized, treatment becomes more complex and often involves multiple approaches.^[5][12][16]

For the primary tumor, wide resection aims to remove the entire tumor along with a margin of surrounding healthy tissue. This approach reduces the risk of cancer cells being left behind. In cases where tumors are in the arms or legs, limb-sparing surgery may be possible, allowing preservation of the limb while still achieving complete tumor removal.^[14]

When metastases are limited to the lungs and can be safely reached surgically, metastasectomy (surgical removal of the lung metastases) may be considered. If the cancer has spread to only a few spots in the lungs and those tumors can be completely removed, surgery can potentially improve outcomes.^[12]

Radiation therapy plays a limited but important role in treating chondrosarcoma. Traditional chondrosarcomas are relatively resistant to standard radiation therapy, requiring higher doses than many other cancers. Radiation is typically reserved for situations where surgery is not feasible, such as tumors in surgically inaccessible locations like the skull base or certain parts of the spine. It may also be used after surgery as adjuvant therapy to help kill any remaining cancer cells, particularly for higher-grade tumors.^[12][14]

Specialized forms of radiation, such as proton therapy, may be used in certain cases to deliver high doses more precisely while minimizing damage to surrounding healthy tissue.^[19]

Chemotherapy is rarely effective for conventional chondrosarcoma. These tumors have developed chemoresistance to standard anticancer drugs, making systemic treatment challenging. However, certain subtypes respond differently to chemotherapy.^[13]

Mesenchymal chondrosarcoma, an aggressive variant, may be treated with chemotherapy regimens similar to those used for other sarcomas. Drug combinations such as vincristine, doxorubicin, and cyclophosphamide, or ifosfamide and etoposide, have been used. When mesenchymal chondrosarcoma has already metastasized at diagnosis, various chemotherapy protocols may be attempted.^[14]

Dedifferentiated chondrosarcoma may be treated with chemotherapy regimens similar to those used for osteosarcoma, another type of bone cancer. These typically include combinations of methotrexate, doxorubicin, and cisplatin. Despite these efforts, outcomes remain poor, and chemotherapy is often considered palliative rather than curative in advanced cases.^[12][14]

Research into new treatments is ongoing. Scientists are investigating molecule-targeting agents and immunotherapy approaches that might offer new hope for patients with advanced chondrosarcoma. Several clinical trials are exploring drugs that target specific molecular pathways involved in chondrosarcoma growth. While some of these agents have shown promise in laboratory studies and early clinical trials, they are not yet standard treatment.^[13]

Because there is no established treatment protocol for high-grade conventional chondrosarcoma and dedifferentiated chondrosarcoma, treatment decisions must be individualized. Patients and families are encouraged to seek second or third opinions and to consider participating in clinical trials when available. Clinical trials offer access to new therapies that may not be available otherwise and contribute to advancing knowledge about this rare cancer.^[19]

For patients with metastatic disease, palliative care becomes an essential component of treatment. Palliative approaches focus on managing symptoms, controlling pain, maintaining quality of life, and providing emotional and psychological support. This type of care can be provided alongside other treatments and is not limited to end-of-life situations.^[12]